Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2010
06/02/2010CN101716140A Sea urchin rhizoma polygonati polysaccharide injection and preparation method thereof
06/02/2010CN101716134A 2-methoxyestradiol transdermal liniment and 2-methoxyestradiol transdermal patch
06/02/2010CN101585757B Method for preparing curcumin, demethoxycurcumin and bisdemethoxycurcumin
06/02/2010CN101371820B Anticancer sustained-release agent containing methotrexate potentiating agent
06/02/2010CN101338321B Method for constructing and screening miRNAs expression vector of stomach cancer target FUT3 gene and uses thereof
06/02/2010CN101333524B Small molecule noncoding RNA gene hsa-mir-101 and antineoplastic use thereof
06/02/2010CN101275134B Medicament for curing breast carcinoma and special antisense oligonucleotide therefor
06/02/2010CN101270154B Cyclo-pentapeptide with antineoplastic activity
06/02/2010CN101255124B Cinnamide histone deacetylase inhibitor and preparation method thereof
06/02/2010CN101249266B Nano liver target direction amphipathic nature block copolymers drug administration system and preparation
06/02/2010CN101239040B Celastrol liposome and preparation thereof
06/02/2010CN101234951B Biphenyls compound and its preparation method and application
06/02/2010CN101229199B Integrative extract method of multi-active ingredient in cordyceps militaris mycelium
06/02/2010CN101229158B Medicine compounds for treating tumour and applications thereof
06/02/2010CN101229131B Novel type nanometer particle preparation capable of reducing gastroenteritic toxicity of camptothecin medicines
06/02/2010CN101224215B Uses of ursolic acid saponin and oleanolic acid saponin in preparing medicine for increasing white blood cell and/or blood platelet
06/02/2010CN101220044B Telomerase inhibitor, preparation method and application thereof
06/02/2010CN101199563B Use of Loosestrife total saponine in preparing medicine for treating liver cancer
06/02/2010CN101182332B Manganese complexes having antitumor and affecting mitochondria functions and its preparation method
06/02/2010CN101181260B Rabdosia nail element clathrate and pharmaceutical preparation containing the same
06/02/2010CN101167820B External-applied traditional Chinese medicine for curing uterus cancer and its preparation method
06/02/2010CN101148437B Biinomenine derivative connected with C-C bond, preparation method and application thereof
06/02/2010CN101143902B Anti-HER2 single-chain antibody-cefuroxime sodium enhanced fusion protein HER2(Fv-LDM)
06/02/2010CN101139350B Oridonin derivative, preparation method and uses thereof
06/02/2010CN101091769B Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method
06/02/2010CN101066437B Detection method for compound cantharis oral liquid
06/01/2010US7728113 Methods of treating arthritic conditions with antibodies to M-CSF
06/01/2010US7728111 Anti-p55 TNF receptor antibody
06/01/2010US7728109 Antagonistic anti-hTNFSF13b human antibodies
06/01/2010US7728016 Substituted 5-membered ring compounds and their use
06/01/2010US7728010 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
06/01/2010US7728007 Therapeutic amides
06/01/2010US7727998 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
06/01/2010US7727980 Tricyclic androgen receptor modulator compounds and methods
06/01/2010US7727735 Detection and treatment of prostate cancer
06/01/2010US7727536 EG-VEGF nucleic acids and polypeptides and methods of use
06/01/2010US7727530 Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
06/01/2010US7727526 Use of PTHrP antagonists for treating renal cell carcinoma
06/01/2010US7727519 Method for treating hepatitis C virus with omega interferon
06/01/2010US7727275 Drug-delivery endovascular stent and method of forming the same
06/01/2010CA2457965C Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives
06/01/2010CA2431888C Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
06/01/2010CA2415169C Novel c-4 substituted retinoids
06/01/2010CA2409827C Arylmethylamine derivatives for use as tryptase inhibitors
06/01/2010CA2400626C Estrogen receptor modulators
06/01/2010CA2384064C Vaccine against herpes simplex virus and human papilloma virus
06/01/2010CA2366750C (e)-styryl sulfone anticancer agents
06/01/2010CA2353816C Compositions and methods for enhancement of major histocompatibility complex class i restricted antigen presentation
06/01/2010CA2221495C Methods and uses for apoptin
05/2010
05/27/2010WO2010060018A1 Azo and diaza derivatives and uses thereof in phototherapy
05/27/2010WO2010059969A2 Anti-angiogenesis therapy for the treatment of breast cancer
05/27/2010WO2010059963A2 Preparation and methodology of silk fibroin nanoparticles
05/27/2010WO2010059916A2 Preparation of docetaxel
05/27/2010WO2010059858A1 Manassantin compounds and methods of making and using same
05/27/2010WO2010059821A1 Anti-unc5b antibodies and methods of use
05/27/2010WO2010059795A1 Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
05/27/2010WO2010059788A1 Pyrazolopyridine pi3k inhibitor compounds and methods of use
05/27/2010WO2010059771A1 Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
05/27/2010WO2010059711A1 Sigma-1 receptor ligands and methods of use
05/27/2010WO2010059589A1 Anticancer combination comprising docetaxel and an antisense oligonucleotide
05/27/2010WO2010059575A2 Combination therapy for the treatment of cancer
05/27/2010WO2010059401A2 Compounds that expand hematopoietic stem cells
05/27/2010WO2010059253A2 Methods and compositions for localized agent delivery
05/27/2010WO2010059239A2 Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
05/27/2010WO2010059004A2 Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient
05/27/2010WO2010059001A2 Polymer micelle composition for treatment of resistant cancer cells
05/27/2010WO2010058846A1 4,6-diaminonicotinamide compound
05/27/2010WO2010058819A1 Peptide capable of inhibiting interaction between human tumor protein mdm2 and human tumor suppression protein p53, and use thereof
05/27/2010WO2010058794A1 Antioxidant
05/27/2010WO2010058572A1 Methods for diagnosing or treating prostate cancer
05/27/2010WO2010058417A1 Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof
05/27/2010WO2010058416A1 Quinazolinone linked pyrrolo[2,1 -c][1.4]benzodiazepine hybrids as potential anticancer agents and process forthe preparation thereof
05/27/2010WO2010058318A1 1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
05/27/2010WO2010058280A1 Auto magnetic metal salen complex compound
05/27/2010WO2010058242A1 New formulations with anti-neoplastic activity
05/27/2010WO2010058032A2 New compounds
05/27/2010WO2010058006A1 Cdk inhibitor for the treatment of mesothelioma
05/27/2010WO2010057981A1 Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
05/27/2010WO2010057962A2 Crf conjugates with extended half-lives
05/27/2010WO2010057877A1 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
05/27/2010WO2010057596A2 New therapy and medicament using integrin ligands for treating cancer
05/27/2010WO2010057430A1 Polymorph form l of erlotinib, methods of preparation and uses thereof
05/27/2010WO2010057418A1 A phenoxypyrimidine derivative, its preparation method and the use thereof
05/27/2010WO2010057275A1 Cyclic peptides and uses thereof
05/27/2010WO2010042638A3 Hpma - docetaxel or gemcitabine conjugates and uses therefore
05/27/2010WO2010040051A3 Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells
05/27/2010WO2010033866A3 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
05/27/2010WO2010019864A3 Ficus extracts having angiogenesis inhibiting activity and methods of isolating and using the same
05/27/2010WO2010019775A3 Methods of treating ras driven cancer in a subject
05/27/2010WO2010019549A3 Indoprofen derivatives for promoting bone growth
05/27/2010WO2010003009A3 Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors
05/27/2010WO2010002465A3 Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
05/27/2010WO2009068955A3 Polymorphs of a c-met/hgfr inhibitor
05/27/2010US20100132073 Sesquiterpenoid modifying enzymes
05/27/2010US20100130729 Mu-1, member of the cytokine receptor family
05/27/2010US20100130728 Taci-immunoglobulin fusion proteins
05/27/2010US20100130598 Methods for inducing programmed cell death
05/27/2010US20100130596 Rad51 derived cancer cell specific promoters for targeted anti- cancer therapy
05/27/2010US20100130592 RNA Interference Mediated Inhibition of GRB2 Associated Binding Protein (GAB2) Gene Expression Using Short Interfering Nucleic Acid (siNA)
05/27/2010US20100130589 MODULATION OF eIF4E EXPRESSION
1 ... 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 ... 2211